Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.

Andes D, Ambrose PG, Hammel JP, Van Wart SA, Iyer V, Reynolds DK, Buell DN, Kovanda LL, Bhavnani SM.

Antimicrob Agents Chemother. 2011 May;55(5):2113-21. doi: 10.1128/AAC.01430-10. Epub 2011 Feb 7.

2.

Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials.

Nucci M, Anaissie E, Betts RF, Dupont BF, Wu C, Buell DN, Kovanda L, Lortholary O.

Clin Infect Dis. 2010 Aug 1;51(3):295-303. doi: 10.1086/653935.

PMID:
20578829
3.

Population pharmacokinetics of micafungin in neonates and young infants.

Hope WW, Smith PB, Arrieta A, Buell DN, Roy M, Kaibara A, Walsh TJ, Cohen-Wolkowiez M, Benjamin DK Jr.

Antimicrob Agents Chemother. 2010 Jun;54(6):2633-7. doi: 10.1128/AAC.01679-09. Epub 2010 Mar 22.

4.

Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.

Horn DL, Ostrosky-Zeichner L, Morris MI, Ullmann AJ, Wu C, Buell DN, Kovanda LL, Cornely OA.

Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):223-9. doi: 10.1007/s10096-009-0843-0. Epub 2009 Dec 15.

PMID:
20013016
5.

Safety and pharmacokinetics of repeat-dose micafungin in young infants.

Benjamin DK Jr, Smith PB, Arrieta A, Castro L, Sánchez PJ, Kaufman D, Arnold LJ, Kovanda LL, Sawamoto T, Buell DN, Hope WW, Walsh TJ.

Clin Pharmacol Ther. 2010 Jan;87(1):93-9. doi: 10.1038/clpt.2009.200. Epub 2009 Nov 4.

6.

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

Smith PB, Walsh TJ, Hope W, Arrieta A, Takada A, Kovanda LL, Kearns GL, Kaufman D, Sawamoto T, Buell DN, Benjamin DK Jr.

Pediatr Infect Dis J. 2009 May;28(5):412-5. doi: 10.1097/INF.0b013e3181910e2d.

7.

Population pharmacokinetics of micafungin in adult patients.

Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL.

Diagn Microbiol Infect Dis. 2008 Mar;60(3):329-31. Epub 2007 Nov 19.

PMID:
18024052
8.

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN.

Clin Infect Dis. 2007 Oct 1;45(7):883-93. Epub 2007 Aug 29. Erratum in: Clin Infect Dis. 2008 Jul 15;47(2):302.

PMID:
17806055
9.

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing.

Hope WW, Seibel NL, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ.

Antimicrob Agents Chemother. 2007 Oct;51(10):3714-9. Epub 2007 Jul 16.

10.

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.

Heresi GP, Gerstmann DR, Reed MD, van den Anker JN, Blumer JL, Kovanda L, Keirns JJ, Buell DN, Kearns GL.

Pediatr Infect Dis J. 2006 Dec;25(12):1110-5.

PMID:
17133155
11.

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis.

Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF.

J Infect. 2006 Nov;53(5):337-49. Epub 2006 May 6.

PMID:
16678903
12.

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN.

Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):654-61. Erratum in: Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):69.

PMID:
16261306
13.

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.

Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ.

Antimicrob Agents Chemother. 2005 Aug;49(8):3317-24.

15.

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ.

Antimicrob Agents Chemother. 2002 Mar;46(3):828-33.

16.

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, Barrett J, Anaissie EJ.

Antimicrob Agents Chemother. 2001 Dec;45(12):3487-96.

17.

Pharmacokinetics, excretion, and mass balance of 14C after administration of 14C-cholesterol-labeled AmBisome to healthy volunteers.

Bekersky I, Fielding RM, Dressler DE, Kline S, Buell DN, Walsh TJ.

J Clin Pharmacol. 2001 Sep;41(9):963-71.

PMID:
11549101
18.

Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine.

Horowitz MM, Przepiorka D, Bartels P, Buell DN, Zhang MJ, Fitzsimmons WE, Erdman J, Huang C, Hodosh E, Maher R, Wingard JR.

Biol Blood Marrow Transplant. 1999;5(3):180-6.

19.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.

Blood. 1998 Oct 1;92(7):2303-14.

20.

Fluconazole versus amphotericin B in the treatment of esophageal candidiasis in cancer patients.

Lake DE, Kunzweiler J, Beer M, Buell DN, Islam MZ.

Chemotherapy. 1996 Jul-Aug;42(4):308-14.

PMID:
8804799
21.

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H, Shadduck RK, Rosenfeld CS, Ho WG, Islam MZ, Buell DN.

Ann Intern Med. 1993 Apr 1;118(7):495-503.

PMID:
8442620
22.

Potential hazards of selenium as a chemopreventive agent.

Buell DN.

Semin Oncol. 1983 Sep;10(3):311-21. Review.

PMID:
6364358
23.

Clinical Oncology Program: a community cancer control model.

Dugan WM Jr, Minnick DJ, Wood JR, Dailey KS, Jansen MA, Lohrman RG, Buell DN.

CA Cancer J Clin. 1979 Sep-Oct;29(5):300-5.

24.

Supportive care: twenty years of progress.

Jaffe N, Buell DN.

Pediatr Ann. 1978 Jul;7(7):508-11. No abstract available.

PMID:
97615
25.
26.

Cell cycle and morphological changes during growth and differentiation of a rat basophilic leukemia cell line.

Buell DN, Fowlkes BJ, Metzher H, Isersky C.

Cancer Res. 1976 Sep;36(9 pt.1):3131-7.

27.

Insulin binding of acute lymphocytic leukemia cells.

Esber EC, Buell DN, Leikin SL.

Blood. 1976 Jul;48(1):33-9.

28.
29.
30.

Autologous human B and T lymphoblastoid cell lines.

Royston I, Smith RW, Buell DN, Huang ES, Pagano JS.

Nature. 1974 Oct 25;251(5477):745-6. No abstract available.

PMID:
4372538
31.

IgD on cell membranes of human lymphoid cell lines with multiple immunoglobulin classes.

van Boxel JA, Buell DN.

Nature. 1974 Oct 4;251(5474):443-4. No abstract available.

PMID:
4608784
32.

Xeroderma pigmentosum long-term lymphoid lines with increased ultraviolet sensitivity.

Andrews AD, Robbins JH, Kraemer KH, Buell DN.

J Natl Cancer Inst. 1974 Sep;53(3):691-3. No abstract available.

PMID:
4416919
33.

Bone-resorbing activity in supernatants from lymphoid cell lines.

Mundy GR, Luben RA, Raisz LG, Oppenheim JJ, Buell DN.

N Engl J Med. 1974 Apr 18;290(16):867-71. No abstract available.

PMID:
4816960
34.

Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture.

Gavin JR 3rd, Roth J, Neville DM Jr, de Meyts P, Buell DN.

Proc Natl Acad Sci U S A. 1974 Jan;71(1):84-8.

35.

Cytotoxicity mediated by human lymphocyte-dependent antibody in a rapid assay with adherent target cells.

Yust I, Wunderlich JR, Mann DL, Buell DN.

J Immunol. 1973 Jun;110(6):1672-81. No abstract available.

PMID:
4712926
36.

Characteristics of the human lymphocyte insulin receptor.

Gavin JR 3rd, Gorden P, Roth J, Archer JA, Buell DN.

J Biol Chem. 1973 Mar 25;248(6):2202-7. No abstract available.

37.

An antigenic marker for human thymic lymphocytes.

Smith RW, Terry WD, Buell DN, Sell KW.

J Immunol. 1973 Mar;110(3):884-7. No abstract available.

PMID:
4540134
38.
39.

Preparation of solubilized insulin receptors from human lymphocytes.

Gavin JR 3rd, Buell DN, Roth J.

Biochem Biophys Res Commun. 1972 Nov 1;49(3):870-6. No abstract available.

PMID:
4344690
40.

Water-soluble insulin receptors from human lymphocytes.

Gavin JR 3rd, Buell DN, Roth J.

Science. 1972 Oct 13;178(4057):168-9.

PMID:
4342623
41.

Proliferation and differentiation of lymphoid cells: studies with human lymphoid cell lines and immunoglobulin synthesis.

Fahey JL, Buell DN, Sox HC.

Ann N Y Acad Sci. 1971 Dec 31;190:221-34. No abstract available.

PMID:
5290016
42.

Multiple myeloma with IgG (lambda) and IgA (lambda) serum M-components: immunohistologic studies.

Rudders RA, Buell DN, Pisciotta AV.

J Lab Clin Med. 1971 Nov;78(5):847-8. No abstract available.

PMID:
5128899
43.

Further characterization of the WI-L1 and WI-L2 lymphoblastoid lines.

Levy JA, Buell DN, Creech C, Hirshaut Y, Silverberg H.

J Natl Cancer Inst. 1971 Mar;46(3):647-54. No abstract available.

PMID:
4323138
44.

Limited periods of gene expression in immunoglobulin-synthesizing cells.

Buell DN, Fahey JL.

Science. 1969 Jun 27;164(3887):1524-5.

PMID:
4182344
45.

Biosynthetic and structural studies of a heavy chain disease protein.

Ein D, Buell DN, Fahey JL.

J Clin Invest. 1969 Apr;48(4):785-93.

46.

THE RELATIONSHIP OF GAMMA-1A GLOBULIN AND REAGIN IN CORD SERA.

ALLANSMITH M, BUELL DN.

J Allergy. 1964 Jul-Aug;35:339-45. No abstract available.

PMID:
14193186
47.

DEMONSTRATION OF GAMMA-2 GLOBULIN IN HUMAN SKIN.

ALLANSMITH M, GOIHMAN-YAHR M, BUELL DN.

J Allergy. 1964 Jul-Aug;35:313-21. No abstract available.

PMID:
14193183

Supplemental Content

Loading ...
Support Center